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SerpinB2 regulates stromal remodelling and local invasion
in pancreatic cancer
NLE Harris1,2,3,9, C Vennin4,5,9, JRW Conway4,5, KL Vine1,2,3, M Pinese4, MJ Cowley4, RF Shearer4,5, MC Lucas4,5, D Herrmann4,5, AH Allam4,
M Pajic4,5, JP Morton6, Australian Pancreatic Cancer Genome Initiative, AV Biankin7, M Ranson1,2,3, P Timpson4,5 and DN Saunders4,8
Pancreatic cancer has a devastating prognosis, with an overall 5-year survival rate of ~ 8%, restricted treatment options and
characteristic molecular heterogeneity. SerpinB2 expression, particularly in the stromal compartment, is associated with reduced
metastasis and prolonged survival in pancreatic ductal adenocarcinoma (PDAC) and our genomic analysis revealed that SERPINB2 is
frequently deleted in PDAC. We show that SerpinB2 is required by stromal cells for normal collagen remodelling in vitro, regulating
fibroblast interaction and engagement with collagen in the contracting matrix. In a pancreatic cancer allograft model, co-injection
of PDAC cancer cells and SerpinB2− /− mouse embryonic fibroblasts (MEFs) resulted in increased tumour growth, aberrant
remodelling of the extracellular matrix (ECM) and increased local invasion from the primary tumour. These tumours also displayed
elevated proteolytic activity of the primary biochemical target of SerpinB2—urokinase plasminogen activator (uPA). In a large
cohort of patients with resected PDAC, we show that increasing uPA mRNA expression was significantly associated with poorer
survival following pancreatectomy. This study establishes a novel role for SerpinB2 in the stromal compartment in PDAC invasion
through regulation of stromal remodelling and highlights the SerpinB2/uPA axis for further investigation as a potential therapeutic
target in pancreatic cancer.
Oncogene (2017) 36, 4288–4298; doi:10.1038/onc.2017.63; published online 27 March 2017
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) represents ~ 92% of all
pancreatic cancers and is one of the deadliest of all solid
malignancies, with a 5-year survival rate of 8%.1 PDAC is often
resistant to therapy owing to intrinsic chemoresistance, hypovas-
cularity and an extensive desmoplastic reaction that creates a
barrier of fibrotic tissue preventing drug penetration.2 As a result,
established approaches to pancreatic cancer therapy (that is
surgical resection and Gemcitabine/Abraxane treatment)3,4 show
low efficacy—with only 25–30% of patients responding5—and
have limited impact on metastatic disease. Aside from frequent
K-Ras mutations (490% of tumours), we have shown that PDAC is
characterized by a high degree of molecular heterogeneity,
making identification of suitable candidates for targeted therapy
challenging.6–8 Advances in adjuvant and metastatic chemother-
apeutic regimens have resulted in modest improvements in
outcome; however, pancreatectomy remains the single most
effective and the only potentially curative modality for the ~ 20%
of patients suitable for such a procedure.
PDAC is characterized by a significant abundance of activated
fibroblasts and other stromal cells such as stellate cells, and these
have been implicated as major facilitators of disease
progression,9–14 where reduced stromal integrity is associated
with enhanced tumour growth, invasion and metastasis. Despite
this increased interest, our understanding of tumour-stromal
interactions in PDAC remains relatively poor and is likely hindering
the development of effective therapies.
The plasminogen activation system (PAS) plays a key role in
tumour invasion and metastasis—increasing the capacity to
breakdown tissue barriers through generation of the proteolytic
enzyme plasmin by tumour and stromal cells.15 The main activator
of the PAS is the serine protease urokinase (urokinase plasmino-
gen activator (uPA)). Overexpression of uPA is an important
biomarker of metastatic disease and it is being actively
investigated as a therapeutic target.15–17 Upon binding to its
cellular receptor, uPAR, the pro-uPA zymogen is catalytically
converted into its active form, which in turn activates co-localized
plasminogen into the broad-spectrum protease, plasmin. The
combined signalling and proteolytic outputs of this pathway
activate a plethora of downstream events driving extracellular
matrix (ECM) degradation, cell proliferation, adhesion and
migration.18 Negative regulation of this pathway occurs at several
levels, including inhibition and clearance of protease activity by
naturally occurring inhibitors, such as SerpinB2 and SerpinE1
(Plasminogen Activator Inhibitors, PAI-2 and PAI-1,
respectively).15,19 Elevated SerpinB2 expression has been linked
with prolonged survival, decreased metastasis or decreased
tumour growth in a number of cancer types,15 including three
small-scale studies in human PDAC.20,21
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Even though SerpinB2 is clearly implicated in PDAC progression,
cell-specific studies have yet to be undertaken to understand the
role of SerpinB2 in specific cell compartments. For example,
SerpinB2 expression in oesophageal squamous cell carcinoma-
associated fibroblasts correlated with prolonged patient survival.22
Furthermore, analysis of expression array data from isolated human
breast tumours and matched normal stroma23 identified a
significant (~16x; Po0.0001) reduction in SerpinB2 expression in
stroma from invasive carcinoma compared with normal breast. Only
a few clinical studies have looked closely at cell-specific expression
in human PDAC,24–26 with varying results that may be confounded
by limited sample sizes. Given these limitations, we applied 3D
organotypic culture27–30 and in vivo allografts using cells from a
mouse model of pancreatic cancer (Pdx1-Cre, LSL-KRasG12D/+, LSL-
Trp53R172H/+, KPC model) that closely recapitulate the human
disease,31–33 and SerpinB2 deficiency,34 to investigate the role of
SerpinB2 in the PDAC tumour microenvironment. Using these
models we demonstrate that SerpinB2 regulates stromal remodel-
ling of collagen, in turn influencing tumour growth and invasion.
RESULTS
Frequent genomic alterations of plasminogen activation system
genes in PDAC
In the specific context of pancreatic cancer, expression of various
individual components of the PAS has been associated with
differential survival or outcome in a small cohort of PDAC
patients.24,26 Across a panel of cancer types, genomic alterations
of PAS component genes (SERPINB2, PLAU, PLAUR, SERPINE1)
were most frequently observed in a PDAC cohort (University of
Texas - Southwestern (UTSW) cohort,35 42% of 109 cases,
Figure 1a), with deep deletion of SERPINB2 in 24% of these cases.
Interestingly, genomic alterations of either the enzyme (PLAU),
receptor (PLAUR) or inhibitors (SERPINB2, SERPINE1) of the PAS
pathway appeared to be mutually exclusive in PDAC (Figure 1b).
These data highlight the potential importance of the PAS system,
in particular loss of SerpinB2, in PDAC.
Stromal SerpinB2 is necessary for fibroblast-contracted collagen I
matrix formation and integrity during ECM remodelling
Stromal expression of SerpinB2 has been linked to progression in a
number of tumour types.15 To investigate the role of stromal
SerpinB2 in the regulation of PDAC stromal remodelling, we used
wild-type or SerpinB2− /− mouse embryonic fibroblasts (MEFs) to
drive collagen contraction in vitro. Interestingly, collagen matrices
formed by SerpinB2− /− MEFs showed significant structural differ-
ences to those generated by wild-type MEFs (Figure 2). After
a 12-day contraction period wild-type MEF-contracted collagen I
matrices were on average 2.3x smaller than those contracted by
SerpinB2− /− MEFs (Figure 2a and b), corresponding to a 58%
reduction in the rate of matrix contraction in the absence
of SerpinB2 (Figure 2b). Second harmonic generation (SHG)
imaging is a label-free, two photon microscopy technique used
to image fibrillar, crosslinked collagen in tissue. SHG analysis of
fibrillar collagen after the 12-day contraction period showed
a significant decrease in fibrillar collagen in the absence of SerpinB2
(Figures 2c–e; Supplementary Movies S1–S4). In wild-type matrices,
maximum SHG intensity signal was 31.58 (s.e.m. = 3.84) while
maximum SHG signal only reached 11.39 (s.e.m.= 1.34) in
SerpinB2− /− matrices (Figure 2e; Supplementary Movie S5). Similar
results were observed using a second, independently derived set of
wild-type and SerpinB2− /− MEF isolates (Supplementary Figure S4),
indicating that additional variant factors do not contribute to these
differences in matrix contraction rates and integrity. Scanning
electron microscopy (SEM) imaging showed extensive fibril
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Figure 1. The SERPINB2 gene is frequently deleted in PDAC. (a) Alteration frequencies of the PAS component genes SERPINB2, PLAU, PLAUR
and SERPINE1 across various cancer types in the cBIO cancer genomics database. (b) Oncoprint showing mutual exclusivity of SERPINB2 PLAU,
PLAUR and SERPINE1 genomic alterations in pancreatic tumours in the UTSW dataset (n= 109).
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coverage, robust outer matrix structure and homogenous, isotropic
collagen distribution in wild-type matrices (Figures 2f and h).
Conversely, SerpinB2− /− MEFs formed disordered, anisotropic
collagen networks, with SEM revealing dense collagen bundles
distributed in an unregulated fashion and resulting in poor collagen
network integrity (Figures 2g and i). Hence, expression of SerpinB2
in stromal cells is required for collagen remodelling in vitro.
In order to further understand the effect of SerpinB2 on matrix
contraction, live imaging of collagen remodelling by green
fluorescent protein (GFP)-labelled fibroblasts was performed at
day 6 of contraction and over a 14-h period. We observed
significant differences in the morphology and behaviour of wild-
type versus SerpinB2− /− MEFs (Figure 3a). Wild-type MEFs
appeared more spread out and were highly mobile, moving
freely throughout the matrix, while SerpinB2− /− MEFs were
significantly less mobile (Figures 3b–d; Supplementary Movie
S6). Notably, wild-type MEFs were predominantly multipolar, with
dynamic cycling of numerous and short protrusions. In contrast,
SerpinB2− /− MEFs were predominately bipolar—with fewer but
longer and more stable protrusions observed (Figures 3e and f).
Hence, the ability of MEFs to stably interact and engage with
collagen within the contracting collagen matrix is significantly
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Figure 2. Fibroblast-derived SerpinB2 is necessary for efficient collagen I matrix contraction. (a) Photographs showing collagen I matrix
contraction over 12 days in the presence of either wild-type or SerpinB2− /− MEFs. (b) Changes in area (mm2) of collagen matrices shown in
(a) over the 12-day contraction period. (c, d): Maximum projection through 0–80 μm z-stack of SHG signal intensity of collagen I matrices
formed with either (c) wild-type or (d) SerpinB2− /− MEFs (e) Quantification of SHG signal intensity within matrices formed by either wild-type
or SerpinB2− /− MEFs, inset: mean SHG signal peak. (f–i) SEM ultrastructure analysis showing surface (f, g) or sagittal section (h, i) of collagen I
matrices. Values shown are mean± s.e.m. from three separate experiments, statistical analysis performed using an unpaired t-test.
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modified in the absence of SerpinB2, and this altered behaviour is
likely responsible for the observed structural changes in matrix
formed by SerpinB2− /− MEFs (Figure 2).
Stromal SerpinB2 suppresses PDAC tumour growth and local
invasion in mixed cell allografts
To determine the effects of modulating SerpinB2 expression in the
stroma in vivo, we performed an allograft experiment where PDAC
cells and MEFs (wild-type or SerpinB2− /−) were co-injected into
nude mice (Figure 4a). We used a MEF:PDAC ratio of 3:1 to reflect
the high fibroblast content and low tumour cellularity of PDAC
tumours.36–38 Seven days post inoculation (see imaging schedule
—Figure 4a), PDAC tumours formed with SerpinB2− /− MEFs were
larger and more elongated than those formed with wild-type
MEFs (mean length 9.7 mm±0.5 versus 7.8 mm±0.7, respectively,
Figure 4b). IHC analysis of tumour cell proliferation
showed significantly elevated Ki-67 staining in tumour cells
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Figure 3. SerpinB2 is necessary for efficient migration of MEFs during collagen I matrix contraction. (a) Migration of wild-type or SerpinB2− /−
MEFs through collagen I matrices was tracked over 14 h at day 6 of contraction. Collagen (magenta) was detected using SHG and wild-type or
SerpinB2− /− MEFs were detected through stable GFP expression. Cell tracks are marked by a vector tail (white). (b, c) Polar plots denoting cell
directionality (x,y distance) and total displacement (μm) of either wild-type (b) or SerpinB2− /− (c) MEFs through collagen I matrices over the
time course (14 h) of the experiment. (d) Normalized motility of wild-type or SerpinB2− /− MEFs through collagen I matrices was computed by
tracking cell position over time (mean± s.em. from three separate matrices). (e) Average number of protrusions per cell over time (mean± s.e.
m. across five time points). (f) Average length of protrusions per cell across the course of the experiment (mean± s.e.m. across five time
points). Statistical analyses were performed using unpaired t-tests.
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of the SerpinB2− /− MEF tumours compared to those formed with
wild-type MEFs (tumour border = 819± 53.3 versus 506 ± 48.1
positive cells per field of view, Po0.01; tumour centre = 576±
65.7 versus 208 ± 48.2 positive cells per field of view, Po0.01;
Figure 4c).
Consistent with in vitro experiments, we also observed
significant changes in collagen matrix remodelling of allograft
tumours in the absence of stromal SerpinB2. SHG analysis
(Figure 4d) showed a significant decrease in collagen content at
tumour margins in the absence of MEF SerpinB2 (mean SHG
signal intensity 28.7 ± 5.8 versus 11.2 ± 1.9 in wild-type versus
SerpinB2− /− MEFs, respectively; P= 0.02). Quantification of col-
lagen I and III content in allografts by picrosirius red staining
(Figure 4e) revealed significantly decreased collagen coverage in
tumours formed with SerpinB2− /− MEFs compared to wild-type
(48.4 ± 10.1% versus 3.5 ± 0.6%, respectively; P= 0.0021).
Examination of allograft tumour margins by immunofluores-
cence (Supplementary Figure S2) showed that many cells were
positive for alpha-smooth muscle actin, marking activated
fibroblasts, which are known to influence tumour progression and
invasion.39 This analysis also showed significantly higher expres-
sion of uPA in tumours formed with SerpinB2− /− MEFs compared
to those formed with wild-type MEFs (Supplementary Figure S2A).
Furthermore, uPA antigen distribution appears to be localized
to discrete regions within tumours formed with wild-type MEFs,
with a more homogenous distribution observed in tumours
formed with SerpinB2− /− MEFs (Supplementary Figure S2A). As
expected, while some cells showed clear expression of SerpinB2 in
tumours formed with wild-type MEFs, very little SerpinB2 was
detected in tumours from SerpinB2− /− MEFs (Supplementary
Figure S2B).
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Figure 4. Stromal SerpinB2 attenuates PDAC tumour growth in mixed cell allografts. (a) A mixture of MEFs (wild-type or SerpinB2− /−) and
PDAC cells (at a 3:1 MEF:PDAC ratio) were inoculated s.c. into nude mice and allowed to grow for 7 days prior to euthanasia and tissue
collection. (b) IVIS imaging of MEF-GFP fluorescence; tumour volume quantification (mean± s.e.m., n= 5). (c) Ki-67 staining and quantification
at both the border and centre of tumours (with insets showing high magnification view). (d) Maximum projection of SHG signal intensity
within MEF:PDAC tumours and quantification of SHG signal (inset shows intensity of SHG signal peak). (e) Picrosirius staining (with insets
showing high magnification view) and quantification of collagen I/III coverage of tumours. Individual values shown are means from three
representative images per tumour, from five animals per group with mean± s.e.m. denoted. Statistical analyses were performed using
unpaired t-tests.
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Histological analysis of excised tumours showed a clear role for
stromal SerpinB2-mediated regulation of uPA activity in driving
local invasion. Tumours formed with wild-type MEFs were largely
encapsulated, with well-defined margins and little evidence of
invasion into surrounding muscle (Figure 5a) or fat (Figure 5c).
In contrast, tumours formed with SerpinB2− /− MEFS had poorly
defined margins (Figures 5a and c). Tumour boundaries were
compromised, with tumour invasion into both muscle (Figure 5a)
and fat (Figure 5c) clearly observed. These qualitative differences
are reflected by a significant increase in local invasion score in
tumours formed with SerpinB2− /− MEFs compared to wild-type
MEFs (Figures 5b and d) using the scoring system described in
Supplementary Figure S3. These data clearly show that SerpinB2
inhibits PDAC local invasion, likely via regulation of stromal
collagen remodelling.
As the canonical role of SerpinB2 is the specific, rapid inhibition
and clearance of cell surface-bound uPA,19,40–42 this function may
also be relevant to the observed effects on PDAC invasion in vivo.
To this end we measured uPA proteolytic activity in tumour
allograft homogenates. The increased local invasion of tumours
formed with SerpinB2− /− MEFs was associated with increased uPA
proteolytic activity in these tumours (250.4 ± 51.1 IU/mg versus
654.9 ± 136.0 IU/mg in wild-type and SerpinB2− /−, respectively;
Po 0.05) (Figure 5e).
PLAU expression is associated with poorer survival following
pancreatectomy
Our observation of increased uPA activity in mixed-cell allograft
tumours formed with SerpinB2− /− MEFs is consistent with the
well-established role of uPA in invasion and metastasis across a
range of cancer types.15 We therefore examined the association
between mRNA expression of the uPA encoding gene, PLAU, and
disease-specific survival in a second, independent cohort of
patients with resected PDAC (Australian Pancreatic Cancer
Genome Initiative (APGI)).7 Increasing PLAU expression was
significantly associated with poorer survival following pancrea-
tectomy (Figures 6a and b; Cox model coefficient 0.387, likelihood
ratio P= 0.00019, n= 141). This corresponds to an approximate
doubling of median survival time from diagnosis between the
10th and 90th percentiles for uPA expression. Case-to-case
matched analysis of SerpinB2, PLAU and PLAUR mRNA expression
in this independent cohort showed that SerpinB2 mRNA levels
were at the threshold of detection in many cases (Supplementary
Figure S5), consistent with the frequent gene deletion we
observed in the UTSW data set (Figure 1). Further, many of the
samples with below-threshold SerpinB2 mRNA detection levels
have high PLAU and/or PLAUR expression (Supplementary
Figure S5), consistent with increased uPA activity in the mixed-
cell allografts formed with SerpinB2− /− MEFS.
DISCUSSION
Beyond surgery, current PDAC treatment options are limited and
have not substantially improved the survival of patients with
unresectable disease over the past 25 years. There is therefore an
urgent need for better understanding of this disease to provide
new therapeutic strategies to treat advanced disease, as 80% of
patients are unsuitable for pancreatectomy.43 Herein, we identify
SerpinB2 as a regulator of PDAC invasion and stromal remodelling,
and show that its enzymatic target uPA is a marker of PDAC
outcome/survival.
At the genomic level, we observed mutually exclusive altera-
tions of various PAS components in a significant proportion of
PDAC cases. The predicted effects of these different alterations are
functionally equivalent. That is, deletion of SERPINB2 (18q21.33-
q22.1) or the amplification of either its enzyme target PLAU
(10q22.2) or enzyme receptor PLAUR (19q13.31), would have the
comparable effect of increasing uPA proteolytic capacity. Mutually
exclusive genomic alterations within a particular pathway strongly
predict a role for that pathway in driving tumorigenesis.44
Interestingly, amplification of another uPA inhibitor, SERPINE1,
frequently occurred in PDAC. Overexpression of SerpinE1 (PAI-1) is
often associated with poor prognosis, and uPA and SerpinE1 are
among the prognostic markers available in node-negative breast
cancer.15,45,46 Despite being a uPA inhibitor, SerpinE1 over-
expression mediates tumour invasion and metastasis through
well-characterized secondary interactions with the ECM
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component vitronectin and/or endocytosis receptors, which
promote cell proliferation and migration.14 In contrast, SerpinB2
lacks the high affinity endocytosis receptor-binding motif and
cannot bind to vitronectin, and thus inhibits and clears uPA
protease activity, a key step suppressing invasion and metastasis,
without inducing the mitogenic and motogenic signals induced
by SerpinE1.18 We show a strong association between increased
PLAU mRNA expression and decreased survival in a large cohort of
patients with resectable pancreatic cancer—from over 3 years
with low expression to 18 months with high expression. In this
respect, the pattern of genomic alterations in PAS components,
particularly the frequent loss of SERPINB2, is consistent with a role
in PDAC biology.
An important consideration in interpreting genomic data on
whole tumour extracts is the relatively low tumour cellularity, high
stromal content and related desmoplasia that is characteristic of
PDAC.7,47 Therefore, to understand the role of SerpinB2 in PDAC
biology it is critical to consider functional effects in a cell-specific
context. Numerous studies have linked stromal expression of
SerpinB2 to disease progression in various tumour types, including
pancreatic cancer.15 Collagen matrix contraction in the presence
of SerpinB2− /− fibroblasts produced a striking effect on matrix
integrity, demonstrating that SerpinB2 regulates fibroblast-
mediated contraction and their capacity to efficiently remodel
the surrounding matrix. Complementary SHG and SEM analyses of
matrices formed by SerpinB2− /− MEFs revealed anisotropic
dispersal of collagen I, compared with the isotropic distribution
observed in matrices formed with wild-type MEFs.48,49 These data
suggest that SerpinB2 is necessary for fibroblast-dependent
manipulation and remodelling of the ECM. This collagen deposi-
tion/remodelling phenotype is consistent with an in vivo model of
liver parasite infection, in which SerpinB2 deficiency resulted in
reduced collagen deposition and fibrosis.50
We observed significantly decreased movement of SerpinB2− /−
MEFs in organotypic culture, and striking differences in cellular
protrusion dynamics in these cells, suggesting that the effect of
SerpinB2 on matrix remodelling is primarily through a novel role
in regulation of fibroblast motility and interactions with the
surrounding ECM. Given that the primary biochemical function of
extracellular SerpinB2 is inhibition of uPA activity, the potential
role of uPA proteolytic activity in mediating the effect of SerpinB2
on collagen matrix remodelling should be considered in future
studies. Metalloproteinases (MMPs) are considered more impor-
tant in the collagen deposition/contraction stage,51 and many of
these do not require uPA for activation.52 However, in vivo
evidence for uPA-mediated plasmin(ogen) activation of a number
of pro-MMPS including pro-MMP-3, -9 and -13 (which then directly
degrade and remodel ECM) has been reported in aneurysm
models.53 It is thus also possible that in the absence of SerpinB2,
enhanced uPA activity leads to increased activation of pro-MMPs.
An additional or alternative mechanism to explain the effect of
SerpinB2 deficiency on collagen remodelling could also be related
to differential fibroblast activation states of SerpinB2− /− versus WT
MEFs. For example, migratory myofibroblasts play an important
role in collagen contraction, ECM turnover and composition.54
The major histopathological hallmark of PDAC is the high
stromal-to-epithelial ratio associated with fibrosis and
desmoplasia.55 In a mixed allograft model recapitulating this
characteristically high stroma:tumour ratio, we observed a clear
role for stromal SerpinB2 in modulating both collagen remodelling
and local tumour invasion. Mixed cell tumours formed with
SerpinB2-deficient MEFs proliferated more and were significantly
more invasive, with reduced collagen deposition. Hence, the
disrupted stromal architecture induced by SerpinB2 deficiency
had a clear effect on PDAC cell invasion in vivo. There have been
conflicting hypotheses concerning the role of the tumour
microenvironment in PDAC.13,56 Our data show that reduced
stromal integrity is associated with tumour growth and local
invasion, consistent with other recent studies.10–14
Considering that the primary biochemical function of SerpinB2
is as a uPA inhibitor, it is notable that tumours formed with
SerpinB2-deficient MEFs had significantly enhanced uPA proteo-
lytic activity compared to those formed with wild-type MEFs. This
was associated with significantly increased local invasion in
SerpinB2-deficient tumours, suggesting that stromal-derived
SerpinB2 may be regulating extracellular or pericellular proteo-
lysis. Together with the observation of frequent loss of SerpinB2
and/or increased uPA/uPAR expression in multiple PDAC cohorts,
a potential role for uPA proteolytic activity in disease progression
cannot be excluded, and is consistent with our novel clinical data
showing an association between uPA expression and survival in
PDAC. Clinicopathological data in other solid tumours have also
implicated the uPA/SerpinB2 axis in invasion and metastasis.
Hence, in this complex and dynamic in vivo context, SerpinB2 may
have a dual role, regulating both stromal integrity and uPA-
dependent PDAC invasion. Further, these findings provide
biological support for further investigation of the potential of
uPA-targeted therapeutics in pancreatic cancer.
MATERIALS AND METHODS
Gene expression survival analysis
Analysis of alteration frequencies in PAS components across various
tumour types (Figure 1) was performed using the cBioPortal for Cancer
Genomics.20,21 Genomic alterations in PDAC (Figure 1) were performed
using the UTSW cohort35 of 109 cases. Outcome data and gene expression
measurements for the APGI PDAC cohort7 (Figure 6 and Supplementary
Figure S5) are available from the ICGC DCC (https://dcc.icgc.org/). Gene
expression measurements from bulk tumour were made on the Illumina
Human HT-12 V4 platform, and were processed using the Bioconductor
lumi package (v 2.18.0), using ‘bgAdjust.affy’ background subtraction, ‘vst’
transformation and ‘quantile’ normalization. Outcome data were current at
March 2016. The influence of log-expression on disease-specific survival
was examined separately for each probe. Martingale residual plots were
used to assess functional form, and no departures from linearity were
observed. The prognostic significance of each probe was then evaluated
by likelihood-ratio tests, comparing a Cox model with probe log-expression
as a linear predictor, against a marginal model. The influence of
significantly prognostic probes on survival was visualized by plotting the
Cox model predicted hazard ratio against probe log-expression, and
further illustrated by comparing fitted survival curves corresponding to
10th, 50th and 90th percentiles of probe expression. Multiple testing
correction was performed by Holm’s method. All data processing was
performed in the R environment (version 3.1.1, survival package version
2.37–7).
Cell lines and culture conditions
Primary mouse PDAC cells were derived from tumours harvested from
Pdx1-Cre, LSL-KRasG12D/+, LSL-Trp53R172H/+ mice32 and maintained in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine
serum and penicillin/streptomycin 1%. All cell cultures were routinely
monitored for absence of mycoplasma contamination using the MycoA-
lert™ Mycoplasma Detection Kit (Lonza, Switzerland). Spontaneously
immortalized wild-type and SerpinB2− /− MEFs were generated and
cultured as previously described.34 Effects of SerpinB2 deficiency on
collagen matrix contraction were also confirmed using a second,
independently derived set of spontaneously immortalized wild-type and
SerpinB2− /− MEF isolates from littermates (Supplementary Figure S4).
SerpinB2 status of these cells was confirmed by RT-qPCR (data not shown)
and western blot of whole cell lysates (Supplementary Figure S1). Wild-
type and SerpinB2− /− cells expressing GFP were generated by viral
transduction using VSV-G pseudotyped lentivirus encoding pLV411
vector.57 Viral particles were packaged using HEK-293 T cells (CRL-3216,
ATCC, USA) using standard procedures.58 GFP-positive MEFs were enriched
by sorting with a FACS Vantage instrument (Becton Dickinson, USA).
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Organotypic contraction assay
Contraction of collagen I matrices by either wild-type or SerpinB2− /− MEFs
was performed as previously described.30 Briefly, rat-tail tendon collagen
was extracted with 0.5 M acetic acid to a concentration of ~ 2.0 mg/ml.
Contraction to a 3D matrix was conducted by embedding quiescent
fibroblasts (1.0–1.5 × 106 per 12 matrices) into the neutralized collagen I
solution. Detached polymerized matrix in 35 mm Petri dishes was then
allowed to contract for up to 12 days in complete media (Dulbecco’s
modified Eagle’s medium, supplemented with 10% FCS and 1% penicillin/
streptomycin), refreshed every six days.
Histological analysis
Samples were fixed in 10% neutral buffered formalin overnight and
processed using the Leica Peloris Dual Retort tissue processor (Germany).
Histological staining was performed on 4 μm sections deparaffinized in
xylene and rehydrated using graded ethanol washes. Haematoxylin and
eosin and picrosirius red (Polysciences, USA, #24901-250) staining were
performed on a Leica Autostainer XL. Immunohistochemistry was
performed using the Leica Bond RX system. Refer to Supplementary
Table S1 for antibody details. For scoring of invasive index, migration
modality, cell cluster and immunohistochemistry staining, three represen-
tative images per condition were acquired using a bright field microscope
(Leica DM4000).
For immunofluorescence analysis, pancreatic tumour allograft cryosec-
tions (4 μm) were fixed in 100% acetone for 10 min at − 20 °C and air-dried.
Rehydrated sections were blocked and processed with antibodies as
described in Supplementary Table S1. Slides were then mounted with
Vectashield containing DAPI (Vector) and cells imaged using a Leica DMI
6000 SP8 laser scanning confocal fluorescence microscope. Staining
specificity was shown with isotype controls.
Second harmonic generation (SHG) imaging analysis
Second harmonic generation imaging is a label-free, two photon
microscopy technique used to image fibrillar, crosslinked collagen in
tissues. SHG is a photonic process in which two low energy photons are
converted into one photon with twice the incident frequency of the
excitation source.59 SHG signal was acquired through an 80-μm z-stack in
fixed collagen matrices and through a 20-μm z-stack in tumour sections
using a × 20 0.95 NA water immersion objective on an inverted Nikon
TE-2000 microscope body. The excitation source was a Ti:Sapphire femto-
second laser cavity (Coherent Chameleon Ultra II, USA), coupled to a
LaVision Biotec Trim-scope scan-head. 840 ± 20 nm excitation wavelength/
420± 10 nm emission wavelength were used to collect SHG signal from
collagen I fibres. ImageJ (NIH, USA) was used to extract SHG signal intensity
per optical slice.
Tracking of fibroblast movements in collagen I matrices
GFP-tagged wild-type and SerpinB2− /− MEFs were detected using a 920-
nm excitation wavelength and SHG signal derived from collagen fibres was
collected as described above on unfixed matrices. Cells were imaged in the
central part of the matrix (typically where the matrix was thickest for wild-
type MEF matrices) to avoid any potential edge effects. Fibroblast motility
within matrices was tracked by recording cell position (X,Y) versus time
with Imaris 8.0 (Bitplane, USA), using the built-in spots and isosurface
tracking routines (130–160 cells were tracked per experiment). Cells were
excluded from analysis if the cell centroid moved less than one cell
diameter, or exhibited a blebbing phenotype, over the 14-h timecourse.
Furthermore, cells displaying oscillations or shape changes were excluded
from the analysis to minimize artefacts associated with automated analysis.
Using MATLAB (Mathworks, USA) the X,Y coordinates, with the first
coordinates set to 0,0, were plotted for one representative experiment.
Scanning electron microscopy
Fixed specimens were sliced and clamped in a cooling chamber consisting
of a 25 mm×10 mm brass block with a sample chamber groove. The brass
holder containing each sample was plunged into a bath of liquid nitrogen
for 40–45 s and then fractured with a liquid nitrogen cooled blade, to
expose a cross-section surface that was flush with the surface of the brass
block. The cooled holder with the fractured sample was then inserted into
a JEOL 6490LV scanning electron microscope equipped with a secondary
electron detector and a backscattered electron detector (scintillator type)
using acceleration voltages between 10 and 20 kV. Images were recorded
with an integrated JEOL digital image acquisition system.
Mixed cell allograft model
7.5 × 105 MEFs (wild-type or SerpinB2− /−) were mixed with 2.5 × 105 PDAC
cells (1 × 106 cells in total at a 3:1 MEF:PDAC ratio) and injected
subcutaneously into the rear flank of BALB/c-Fox1nuAusb mice (5 per
group). Tumour volume was quantified using a digital vernier caliper and
calculated as: width×width × length/2.60 Mice were monitored daily in
compliance with the Garvan/St Vincent’s Hospital Animal Experimentation
and Ethics Committee guidelines (approval #13/17). Mice were anesthe-
tized 7 days post injection and tumours were imaged using an IVIS system.
Cell invasion into local tissue (subcutaneous fat, muscle and skin) was
analysed by histoscore on 4 μm H&E stained sections. Local invasion was
quantified as shown in Supplementary Figure S3, and scored blind by three
separate researchers.
Urokinase activity assays in tumour lysates were performed as previously
described.61 Briefly, tumours were homogenized in 10 mM Tris, pH 8.0,
0.15 M NaCl, 1% Triton X-100, and lysates diluted in 100 μl reaction buffer
(20 mM HEPES, pH 7.6, 100 mM NaCl, 0.5 mM EDTA, 0.01% (v/v) Tween-20)
containing 0.25 mM uPA fluorogenic substrate (Z-Gly-Gly-Arg-AMC—
Chemicon, USA). Fluorescence was measured kinetically using a POLAstar
plate reader (OMEGA) and activity determined against a murine uPA
standard.
Statistical analyses
Differences in the mean of two groups were analysed by an unpaired
t-test. Comparisons of more than two groups were made by a one-way (or
two-way) ANOVA with post hoc Holm–Sidak analysis for pairwise
comparisons and comparisons versus control. P valueso0.05 were
considered statistically significant. Data and statistical analyses were
performed using GraphPad Prism (version 6.0, USA).
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